BB Biotech Q2 2026 Results
BB Biotech AG (SIX:BION) announced a net profit of CHF 451 million for the second quarter of 2026, a turnaround from the CHF 100 million loss recorded in the same quarter of 2025. The company attributed the profit to broad‑based clinical execution and continued merger‑and‑acquisition activity across its portfolio.
The net asset value (NAV) generated a total return of 17.2 % in Swiss francs, surpassing the Nasdaq Biotechnology Index, which returned 13.7 % in CHF, by 3.5 percentage points. In the same currency, the share‑price total return was 9.7 %. Converting to other currencies, NAV total return was 17.2 % in euros and 15.9 % in U.S. dollars, while share‑price total return was 8.7 % in euros and 8.5 % in dollars. The appreciation of the U.S. dollar during the quarter provided a tailwind for investors holding CHF‑denominated assets.
The discount of the share price to NAV widened to 12.9 % as of 30 June 2026, despite the underlying portfolio’s strong performance. The board of directors approved a revision to the annual payout policy, effective from fiscal year 2026, targeting an annual dividend yield of 3‑5 % of the share price. The first dividend under the new framework is scheduled for spring 2027, with the exact level to be set each year based on investment performance, NAV development, and prevailing market conditions. BB Biotech has paid annual dividends consistently since 2013.
During the quarter, BB Biotech initiated twelve new investments, bringing the total number of positions to 39. These new holdings span commercial‑stage companies, clinical‑stage innovators, and earlier‑stage opportunities across oncology, immunology, neurology, and rare disease. At quarter‑end, the portfolio comprised 37 listed holdings after selective exits.
Three portfolio companies were involved in announced M&A transactions in 2026: Merck’s acquisition of Terns Pharmaceuticals, GSK’s announced acquisition of Nuvalent, and, after quarter‑end, Vertex Pharmaceuticals’ acquisition of Crinetics Pharmaceuticals. Over the past six quarters, a total of eight portfolio companies have been the subject of announced acquisitions.
As of 30 June 2026, the largest holdings were Amgen (8.5 % of securities), Argenx SE (7.9 %), Vertex Pharmaceuticals (7.8 %), and Gilead Sciences (7.4 %). The total value of securities stood at CHF 2.87 billion, other assets were valued at CHF 217.3 million, and other payables amounted to CHF (5.3) million, resulting in a net asset value of CHF 3.08 billion. Approximately 7 % of NAV was available as cash for deployment entering the second half of 2026.
The company highlighted that large pharmaceutical firms face more than $250 billion of revenue at risk from patent expiries through 2030, underscoring the strategic importance of BB Biotech’s investment focus.